Quick access to up-to-date company information.
Newly Published Head-to-Head Data Show STIOLTO™ RESPIMAT® (tiotropium bromide and olodaterol) Improved Lung Function Across Range of Measures
SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray Now Available in the U.S. for Maintenance Treatment of Asthma in Adults and Adolescents
Boehringer Ingelheim’s Gilotrif® (afatinib) demonstrated superiority to Iressa® (gefitinib) in reducing the risk of disease progression and treatment failure in first-line treatment of patients with EGFR mutation-positive advanced non-small cell lung cancer
U.S. FDA Accepts Filing of Cardiovascular Outcomes Data for Jardiance® (empagliflozin)
Boehringer Ingelheim’s third generation EGFR TKI, BI 1482694, receives FDA Breakthrough Therapy Designation for treatment of patients with non-small cell lung cancer
Click here to subscribe to email press release alerts
900 Ridgebury Rd. P.O. Box 368 Ridgefield, CT 06877